Discipline Decisions (January 2022)

The Panel found that Ms. Abanzukwe, while practising as a pharmacist, Designated Manager and/or the sole director and shareholder of the corporation that owned and operated Brock Medical Pharmacy, committed professional misconduct in that she:

• Engaged in the practice of pharmacy while her certificate was suspended from on or around December 1, 2018 to on or around January 31, 2019;
• Falsified records relating to her practice or a person’s health record with respect to one or more identified prescriptions from on or about December 1, 2018 to on or about January 31, 2019;
• Kept medications in inventory without expiration dates and/or lot numbers, in or around February of 2019.

In particular, the Panel found that she:

• Contravened a term, condition or limitation imposed on her certificate of registration;
• Failed to comply with an order of a panel of a Committee of the College;
• Practised the profession while her certificate was under suspension;
• Falsified records relating to her practice or a person’s health record;
• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed acts that, having regard to all the circumstances, would reasonably be regarded by members of the profession as unprofessional, dishonourable and disgraceful.

Referral 2:

The Panel found that Ms. Abanzukwe committed professional misconduct in that she failed to fulfill all requirements related to working with a practice mentor, as ordered by the Discipline Committee on December 8, 2016.

In particular, the Panel found that she:

• Contravened a term, condition or limitation imposed on her certificate of registration;
• Failed to comply with an order of a panel of a Committee of the College;
• Engaged in conduct or performed acts that, having regard to all the circumstances, would reasonably be regarded by members of the profession as unprofessional, dishonourable and disgraceful.

Referral 3:

The Panel found that Ms. Abanzukwe, as a dispensing pharmacist and/or Designated Manager at Remedy’s Rx Brock Medical Pharmacy, and/or as the director and/or sole shareholder of the corporation that owned Remedy’s Rx Brock Medical Pharmacy, committed professional misconduct with respect to the following:

• False or unsubstantiated claims submitted to the Ontario Drug Benefit Program (ODB) from Remedy’s Rx Brock Medical Pharmacy totalling approximately $103,932 for 20 identified drug and other health products, from on or around July 1, 2015 to on or around August 31, 2017; and/or
• Improper claims for prescriptions submitted to the ODB from Remedy’s Rx Brock Medical Pharmacy totalling approximately $19,485, in relation to one or more of certain identified claims.

In particular, the Panel found that she:

• Failed to maintain a standard of the profession;
• Contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular:
  • sections 5, 15, 17 and/or 23 of the Ontario Drug Benefit Act; and/or
  • sections 25 and/or 27 of Ontario Regulation 201/96; and/or
  • sections 155, 156, 163 and/or 166 of the Drug and Pharmacies Regulation Act;
• Failed to keep records as required respecting her patients;
• Submitted an account or charge for services that she knew and/or ought to have known was false or misleading;
• Falsified a record relating to her practice;
• Signed or issued, in her professional capacity, a document she knew or ought to have known contained a false or misleading statement;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and unprofessional.

Referral 4:

The Panel found that Ms. Abanzukwe, as a dispensing pharmacist and/or Designated Manager at Brock Medical Pharmacy, and/or as the director and/or sole shareholder of the corporation that owned Brock Medical Pharmacy, committed professional misconduct in that she:

• Submitted an account or charge for services or products that she knew or ought to have known was false or misleading with respect to one or more of certain identified drugs and/or products, from on or around January 1, 2019 to on or around December 31, 2019;
• Falsified a record relating to her practice or a person’s health record with respect to one or more of certain identified drugs and/or products, from on or around January 1, 2019 to on or around December 31, 2019;
• Signed or issued, in her professional capacity, a document she knew or ought to have known contained a false or misleading statement, with respect to one or more of certain identified drugs and/or products, from on or around January 1, 2019 to on or around December 31, 2019; and/or
• Failed to maintain the integrity Brock Medical Pharmacy’s inventory of zopiclone, resulting in the loss of approximately 836 7.5mg tablets of zopiclone medications, from approximately January 1, 2018 to August 12, 2020.

In particular, the Panel found that she:

• Failed to maintain a standard of practice of the profession;
• Submitted an account or charge for services or products that she knew or ought to have known was false or misleading;
• Falsified a record relating to her practice or a person’s health record;
• Signed or issued, in her professional capacity, a document she knew or ought to have known contained a false or misleading statement;
• Contravened the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, and in particular, sections 155(1), 156, 163, and 166 of the Drug and Pharmacies Regulation Act;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and unprofessional.

At the same on July 19, 2021, a Panel of the Discipline Committee found that 2037424 Ontario Inc., to whom the certificate of accreditation for Brock Medical Pharmacy was issued, and Joy Abanzukwe, the sole director of 2037424 Ontario Inc. and the Designated Manager of Brock Medical Pharmacy, committed an act or acts of proprietary misconduct by refilling, selling and/or renewing prescription drugs without a prescription, between in or around April 11, 2019 and July 17, 2019.

In particular, the Panel found that 2037424 Ontario Inc., to whom the certificate of accreditation for Brock Medical Pharmacy was issued, and Joy Abanzukwe, the sole director of 2037424 Ontario Inc. and the Designated Manager of Brock Medical Pharmacy:

• Contravened the Drug and Pharmacies Regulation Act, the Pharmacy Act, 1991, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act, the Ontario Drug Benefits Act or the regulations under those Acts, including but not limited to section 155 of the Drug and Pharmacies Regulation Act;
• Contravened a federal, provincial or territorial law or any municipal by-law, with respect to the distribution, purchase, sale, dispensing or prescribing of any drug product, the administering of any substance or the piercing of the dermis, where the purpose of the law or by-law is to protect or promote public health, or where the law or bylaw relates to the operation of the pharmacy or the provision of pharmacy services, including but not limited to subsection C.01.041(1)(a) of the Food and Drug Regulations, C.R.C., c. 870, as amended; and
• Engaged in conduct or performed an act relevant to the operation of a pharmacy that, having regard to the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and unprofessional.

Following findings made on July 19, 2021, and after Submissions with respect to Order were heard on July 22, 2021. The Panel issued its Order in a decision dated November 18, 2021, as follows:

1. Directing the Registrar to revoke the Certificate of Registration of Joy Abanzukwe (the “Member”), effective on the date when the Order becomes final.

2. Requiring the Member to appear before the Panel to be reprimanded, within three (3) months of the date when the Order becomes final.

3. Requiring the Member to pay a fine in the amount of thirty-five thousand dollars ($35,000.00) to the Minister of Finance, effective on the date when the Order becomes final.

4. Directing the Registrar to impose terms, conditions and limitations on the Certificate of Accreditation #300274 for Brock Medical Pharmacy (the “Pharmacy”), effective on the date when the Order becomes final, specifically that:

a. The Member shall not act as the Designated Manager of the Pharmacy at any time; and

b. The Pharmacy shall have a Designated Manager approved by the Registrar of the College in place at all times, and if there is no approved Designated Manager in place, then the Pharmacy shall be temporarily closed until a new approved Designated Manager can be found.

5. Directing the Registrar to revoke the Pharmacy’s Certificate of Accreditation #300724, effective on the date that is six (6) months after the date when the Order has become final, if the Pharmacy has not already been permanently closed or sold such that the Member is no longer an owner, shareholder, and/or director by that date.

6. Requiring the Member to pay costs to the College in the amount of fifty-nine thousand dollars ($59,000.00) according to the following payment plan: Five thousand dollars ($5,000.00) on the date when the Order becomes final and then six thousand seven hundred and fifty dollars ($6,750.00) every three (3) months for eight (8) payments.

7. Requiring the Member and/or 2037424 Ontario Inc. to pay costs to the College in the amount of sixteen thousand dollars ($16,000.00), effective on the date when the Order becomes final. This amount is in addition to the amount set out in paragraph 6 above.

Note: this is a global order addressing findings of both professional misconduct and proprietary misconduct.

The reprimand in this matter remains outstanding.

• Failed to maintain accurate records with respect to the provenance and/or purchases of certain identified products;
• Failed to ensure that prescription medications obtained for sale were of acceptable standard and quality, with respect to certain identified products;
• Failed to ensure that prescription medications in stock were properly labelled, with respect to certain identified products.

In particular, the Panel found that he:

• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as dishonourable or unprofessional.

The Panel imposed an Order, as follows:

1. A reprimand;

2. That the Registrar is directed to impose specified terms, conditions or limitations on the Member’s certificate of registration, and in particular:

a. That the Member complete successfully, with an unconditional pass, at his own expense and within twelve (12) months of the date of this Order, the ProBE Program on Professional/Problem Based Ethics offered by the Center for Personalized Education for Professionals;

b. That that the Member pass, within 12 months of the date of this Order and at his own expense, the Ontario College of Pharmacists’ Jurisprudence Exam;

c. That the Member successfully complete, within 12 months of the date of this Order and at his own expense, the Ontario College of Pharmacists’ online Designated Manager Module;

d. That the Member’s practice, and the operation of any pharmacy in which he has a proprietary interest, to be subject to Compliance Audit Reviews (CARs) by the College. The following terms apply to the CARs:

i. the College will be entitled to conduct any CAR for a period of two (2) years from the date of this Order (“CARs Period”);

ii. if the Member ceases to have both a place of practice and a proprietary interest in any pharmacy at any time within the two (2) years specified in subparagraph i above, such that the College is unable to conduct any CARs, then the CARs Period shall be paused and shall resume on the date on which the Member obtains a place of practice and/or a proprietary interest in a pharmacy, and in such circumstances:

1. the Member shall notify the College, in writing, if he no longer has a place of practice and a proprietary interest in a pharmacy at any point(s) during any times that the CARs Period remains active; and

2. if the CARs Period is paused at any time(s), the Member shall notify the College, in writing, when he obtains a place of practice and/or a proprietary interest in a pharmacy, at which point the CARs Period shall resume and shall continue until a total period of two (2) years has been achieved;

iii. the CARs will be conducted by means of attendances by a representative of the College at the Member’s place of practice and/or at any pharmacy in which he holds a proprietary interest, at such times as the College may determine;

iv. during any CAR, the College representative will be entitled to review and examine the Member’s practice, or the practice and operation of any pharmacy in which the Member holds a proprietary interest, with respect to the labelling, standard and quality, and/or provenance of drugs in inventory;

v. the CARs are in addition to any routine inspections conducted by the College pursuant to the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H.4., s. 148, and are not a substitute for such inspections;

vi. the Member shall fully cooperate with the College representative during the CARs; and

vii. the Member shall pay to the College in respect of such CAR the amount of $1,000.00 per CAR, immediately after each CAR is completed, with the total amount to be paid by the Member not to exceed $3,000, regardless of the number of CARs and/or attendances conducted by the College.

3. That the Registrar is directed to suspend the Member’s Certificate of Registration for a period of 5 months with one month of the suspension be remitted on condition that the Member complete the remedial training as specified in subparagraphs 2(a), (b), and (c). The suspension shall commence on October 15, 2021 and shall continue until February 14, 2022, inclusive. If the remitted portion of the suspension is required to be served by the Member because he fails to complete the remedial training as specified in subparagraphs 2(a), (b), and (c), that portion of the suspension shall commence on October 17, 2022, and shall continue until November 16, 2022, inclusive, unless the time for completing the remedial training in subparagraph 2(a), (b), or (c) is extended by the Registrar, in which case, the date on which the remitted portion of the suspension shall commence, if required, shall be adjusted accordingly.

In its reprimand, the Panel noted that Mr. Rosenhek’s conduct brought shame and disrepute onto himself and the profession.

The Panel pointed out that pharmacists are responsible to ensure that medications are managed in a manner that complies with the standards of practice of the profession. Mr. Rosenhek failed to ensure that products purchased were of acceptable standard and quality, and he have failed to ensure that products were properly labelled. He contravened College policy and provincial law.

The Panel expressed its view that Mr. Rosenhek failed in his duties as designated manager and engaged in conduct that poses a risk to public safety.

The Panel relayed its expectation that Mr. Rosenhek will learn from this shameful experience, and will take this opportunity to change his ways by seriously undertaking the rehabilitation measures in the Order.

• Failed to adequately document Pharmacy patients’ missed doses of methadone and/or buprenorphine, from on or about October 22, 2018, to on or about February 14, 2020; and/or
• Failed to document notification of Pharmacy patients’ prescribers of missed patient doses of methadone and/or buprenorphine as required, from on or about October 22, 2018, to on or about February 14, 2020; and/or
• Maintained incomplete and/or inaccurate records with respect to prescriptions billed for patients [Patient 1] and/or [Patient 4], from on or about January 18, 2020, to on or about February 14, 2020; and/or
• Failed to maintain records of Methadose sign-in/observed-dose sheets for certain identified patients, from on or about January 1, 2018, to on or about February 14, 2020.

In particular, the Panel found that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as unprofessional.

The Panel imposed an Order as follows:

1. A reprimand;

2. Directing the Registrar to impose specified terms, conditions or limitations on the Member’s Certificate of Registration, and in particular:

(a) that the Member shall successfully complete, at his own expense and any time before or within 12 months of the date of the Order:

(i) The ProBE Program on Professional/Problem Based Ethics for healthcare professionals, with an unconditional pass

(ii) The Ontario College of Pharmacists’ Online Designated Manager e-learning module

(b) that the Member shall be prohibited from acting as a Designated Manager in any pharmacy, until such time as the Member has successfully completed all the remedial training as specified in paragraph 2(a), above.

2. Directing the Registrar to suspend the Member’s Certificate of Registration for a period of two (2) months, with one (1) month of the suspension to be remitted on condition the Member complete the remedial training program specified in paragraph 2(a), above. The suspension shall commence on the date of this Order and shall continue for one (1) months, without interruption. If the remitted portion of the suspension is required to be served by the Member because he fails to complete the remedial requirement specified in paragraph 2(a), that portion of the suspension shall commence on the date that is twelve (12) months from the date of this Order and shall continue for one (1) month, inclusive. If the time for completing the remedial steps in paragraph 2, above, is extended by the Registrar, the date on which the remitted portion of the suspension shall commence, if required, shall be adjusted accordingly.

3. Costs to the College in the amount of $7,500.

In its reprimand, the Panel noted that Mr. Yassa is a member of the highly respected profession of pharmacy. On behalf of the public and his professional peers, the Panel expressed its disappointment with his actions in this case.

The Panel observed that Designated Managers are accountable and responsible for ensuring that policies and procedures are in place, and adhered to, by all staff in the pharmacy. How busy the pharmacy is, or how challenging patients are, should not affect the adherence to these policies. In fact, such challenging situations are exactly when and where policies should and need to be enforced, as they help to mitigate the risk for errors and ensure patient safety is maintained.

The Panel pointed out the seriousness of Mr. Yassa’s misconduct, given that methadone is a medication that is inherently high risk to both the patient and the public when not dispensed or handled with the utmost caution.

The Panel expressed its expectation that Mr. Yassa will complete the remedial actions and use this as an opportunity to learn from and improve his professional practice, and that he will not appear before a Panel of the Discipline Committee again.

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, or the regulations under those Acts, and in particular, ss. 155 and 156 of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H-4, as amended;
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, ss. 5 and 15(1) of the Ontario Drug Benefit Act, R.S.O. 1990, c. O.10, as amended;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable and unprofessional.

The Panel imposed an Order, as follows:

1. A reprimand;

2. That the Registrar is directed to impose specified terms, conditions or limitations on the Member’s certificate of registration, and in particular:

a. that the Member complete successfully, with an unconditional pass, at his own expense and within 12 months of the date of this Order, the ProBE Program on Professional/Problem-Based Ethics offered by the Center for Personalized Education for Professionals;

b. That the Member shall be prohibited, for a period of three years from the date of this Order:

i. from acting as a Designated Manager of any pharmacy; and

ii. from holding an ownership interest, of any kind, in any pharmacy.

3. That the Registrar is directed to suspend the Member’s Certificate of Registration for a period of 10 months with one month of the suspension to be remitted on condition that the Member complete the remedial training as specified in subparagraph 2(a). The suspension shall commence on October 27, 2021 and shall continue until July 26, 2022, inclusive. If the remitted portion of the suspension is required to be served by the Member because he fails to complete the remedial training as specified in subparagraph 2(a), that portion of the suspension shall commence on October 28, 2022, and shall continue until November 27, 2022, inclusive, unless the time for completing the remedial training in subparagraph 2(a) is extended by the Registrar, in which case, the date on which the remitted portion of the suspension shall commence, if required, shall be adjusted accordingly;

4. Costs to the College in the amount of $10,000.

In its reprimand, the Panel noted that as a shareholder, director, and Designated Manager of the Pharmacy, Mr. Soliman was required to ensure the accuracy of claims to the Ontario Drug Benefit Program, which depends on trust and integrity.

The Panel observed that Mr. Soliman failed to maintain the responsibilities and obligations expected of him as a member of this profession. He breached the Standards of Practice, and failed as a Designated Manager to provide an appropriate level of supervision of the Pharmacy.

The Panel explained that the practice of pharmacy is a privilege, held in high regard. The pharmacy profession comes with significant obligations to the public, the profession, and oneself. The Panel indicated that Mr. Soliman has violated that trust.

The Panel expressed its expectation that Mr. Soliman will reflect and commit to remediation, and that he will change the way he practices and will not appear again before a panel of the Discipline Committee.

• Failed to maintain a standard of practice of the profession;
• Contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, sections 5, 6, and 15 of the Ontario Drug Benefit Act;
• Submitted an account or charge for services that he knew and/or ought to have known was false or misleading;
• Falsified a record relating to his practice and/or a person’s health record;
• Signed or issued, in his professional capacity, a document he knew or ought to have known contained a false or misleading statement;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable and unprofessional.

The Panel imposed an Order, as follows:

1. A reprimand;

2. Directing the Registrar to impose specified terms, conditions or limitations on the Member’s certificate of registration requiring that:

a. the Member successfully complete, at his own expense and within twelve (12) months of the date of the order, the ProBE Program on Professional, Problem-Based Ethics;

b. the Member successfully complete, at his own expense and within eighteen (18) months of the date of the order, a course with Gail E. Siskind Consulting Services, or another professional ethics consultant approved by the College, to be designed by the consultant, but with the general aim of addressing the Member’s conduct addressed in this proceeding, and in particular, in submitting a large volume of false and unsubstantiated claims to a public payor. The following terms shall apply to the course:

i. The number of sessions shall be at the discretion of the consultant, but shall be no fewer than three.

ii. The manner of attendance at the session(s) is a matter to be discussed in advance between the Member and the consultant, but shall ultimately be at the discretion of the consultant.

iii. The Member shall be responsible for the cost of the course.

iv. The Member shall provide to Ms. Siskind, in advance of the course, his essay and any and all evaluations from the ProBE program;

v. The Member shall require Ms. Siskind to report the results of the course to the College no later than eighteen (18) months from the date of this order.

c. For a period of 5 years from the date that the Member obtains an active certificate of registration following the served suspension set out in paragraph 3 below, the Member shall be prohibited from:

i. Having a proprietary interest of any kind in a pharmacy;

ii. Acting as a Designated Manager in any pharmacy; and

iii. Receiving any remuneration for his work as a pharmacist other than remuneration based on hourly or weekly rates only.

d. the Member shall provide notification to any of his employers in pharmacy regarding the disposition of this discipline proceeding, for a period of five (5) years from the date of completion of the served suspension set out in paragraph 3 below, on the following terms:

i. the Member shall notify the College in writing of the name, address, and telephone number of any current or future employer, within fourteen (14) days of resuming any current employment or commencing any future employment in pharmacy;

ii. the Member shall provide his employer(s) in pharmacy with a copy of the Agreed Statement of Facts and this Joint Submission on Order, or the Decision and Reasons of the Discipline Committee in this matter, including this Order, prior to resuming any current employment or commencing any future employment in pharmacy; and

iii. the Member shall only engage in the practice of pharmacy for an employer who agrees to advise the College in writing, within fourteen (14) days of the Member resuming any current employment or commencing any new employment with the employer, confirming that the Designated Manager of the employer’s pharmacy has received a copy of the documents set out in paragraph 2(b)(ii) above.

iv. The terms in clauses 2(d)(i), 2(d)(ii) and 2(d)(iii) shall apply even if the Member’s employment in the pharmacy is as a relief pharmacist.

3. Directing the Registrar to suspend the Member’s Certificate of Registration for a period of thirty-two (32) months, with two (2) months of the suspension to be remitted on condition the Member complete the remedial training program specified in paragraphs 2(a) and 2(b) above. The Suspension shall commence on November 2, 2021, and continue without interruption until May 1, 2024, inclusive. If the remitted portion of the suspension has to be served, the further suspension shall commence on May 2, 2024, and continue without interruption until July 1, 2024, inclusive, unless the time for completing the remedial steps in paragraphs 2(a) and 2(b), above, is extended by the Registrar, in which case, the date the suspension shall commence, if required, shall be adjusted accordingly.

4. Costs to the College in the amount of $15,000.00.

In its reprimand, the Panel noted that the profession of pharmacy is a noble profession. The public expects pharmacists to act ethically, professionally, and with integrity. The Panel related that Mr. Siwani failed to do so.

The Panel explained that practising pharmacy is a privilege that is granted to those who possess the knowledge, skill, and judgement to practice safely, ethically, and professionally.

The Panel observed that Mr. Siwani was the Pharmacy’s Designated Manager, and one of the shareholders and the full director of the Pharmacy when the College’s investigation revealed unsubstantiated ODB claims of over $1,142,000. His misconduct, which continued over a prolonged period, casts serious doubt on his moral fitness to practice this profession.

The Panel expressed its view that the harshness of the Order is appropriate in this case, and that Mr. Siwani’s admission to all of the allegations is a first step towards his rehabilitation.

The Panel concluded that Mr. Siwani must change his ways and learn from this shameful incident.

• Deliveries of prescription drugs to FYP Pharmacy in the absence of a pharmacist and/or to individuals who were not pharmacists and/or employees of FYP Pharmacy;
• The ongoing activities of FYP Pharmacy when it was not entitled to operate from August 10, 2018 through October 2018;
• Failure to comply with the interim order of the Accreditation Committee of the College made in September 2018;
• The sale of medications from [Entity] to [Pharmacy]; and/or
• His failure to respond to communications from the College’s investigator.

In particular, the Panel found that he:

• Failed to maintain a standard of practice of the profession;
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, in particular but not limited to subsection 146(1)(a) of the Drug and Pharmacies Regulation Act;
• Contravened any federal, provincial or territorial law or municipal by-law, i. with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, the administering of any substance, or the piercing of the dermis, ii. whose purpose is to protect or promote public health, or iii. that is otherwise relevant to the member’s suitability to practise, in particular but not limited to the Food and Drugs Act, R.S.C., 1985, c. F-27, and the Food and Drug Regulations, C.R.C., c. 870, as amended;
• Permitted, consented to, approved, counselled or assisted, whether expressly or by implication, the commission of an offence against any Act relating to the practice of pharmacy or the sale of drugs;
• Failed to reply within a reasonable time to a written or electronic inquiry or request from the College;
• Failed to comply with an order of a Committee or a panel of a Committee of the College;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and unprofessional.

Mr. Bedggood agreed to permanently resign as a member of the College while this discipline proceeding was pending.

The Panel imposed an Order which included as follows:

1. A reprimand;
2. Costs to the College in the amount of $10,000.00.

The reprimand in this matter remains outstanding.